All patients (n = 22) | Dieters (n = 15) | Nondieters (n = 7) | Methotrexate (n = 14) | No methotrexate (n = 8) | |
---|---|---|---|---|---|
Treatment used | |||||
Pulsed methylprednisolone† (mg) | 200 (160 to 360) | 200 (160 to 230) | 200 (140 to 730) | 200 (160 to 360) | 200 (120 to 730) |
Chloroquine (n [%]) | 15 (68) | 12 (80) | 3 (43) | 10 (71) | 5 (63) |
Methotrexate (n [%]) | 14 (64) | 10 (67) | 4 (57) | 14 (100) | 0 (0) |
Minocyclin (n [%]) | 9 (41) | 7 (47) | 2 (29) | 7 (50) | 2 (25) |
Azathioprine (n [%]) | 2 (9) | 0 (0) | 2 (29) | 0 (0) | 2 (25) |
Nonmethotrexate DMARD per patient (n)† | 1 (1 to 2) | 1 (1 to 2) | 1 (1 to 1) | 2 (1 to 2) | 1 (1 to 2) |
Changes in cardiovascular risk | |||||
Weight† (kg) | -4 (-6.5 to +0) | -4.6 (-8.6 to -4) | 0 (0 to 0.8) | -3.4 (0 to 8.6) | -4 (-6.2 to 0) |
C-reactive protein† (mg/l) | -14 (-36 to -6)* | -12 (-36 to -5) | -19 (-35 to -13) | -27 (-83 to -6) | -10 (-13 to -3)*** |
Insulin† (μU/ml) | -4.5 (-8.8 to -2.5)* | -3.4 (-7.9 to -1.5) | -6.4 (-11.7 to -2.6) | -4.5 (-10.2 to -2.9) | -4.5 (-6.4 to -1.5) |
Glucose† (mmol/l) | -0.5 (-0.8 to -0.3) | -0.5 (-0.9 to -0.3) | -0.4 (-0.8 to -0.1) | -0.5 (-1.8 to -0.3) | -0.5 (-0.8 to +0.1) |
HOMA† (μU . mmol/ml . l) | -0.95 (-1.49 to -0.50)* | -0.89 (-2.20 to -0.76) | -1.45 (-2.92 to +0.82) | -1.08 (-2.99 to -0.85) | -0.87 (-0.20 to -0.49) |
QUICKI† | 0.023 (0.014 to 0.049)* | 0.021 (0.009 to 0.042) | 0.035 (0.023 to 0.046) | 0.026 (0.042 to 0.015) | 0.022 (0.045 to 0.007) |
Total cholesterol† (mmol/l) | -0.05 (-0.9 to +0.5) | -0.6 (-1.2 to 0.0) | 0.8 (0.2 to 0.9)* | 0.0 (-0.5 to +0.7) | -0.35 (-1.7 to +0.9) |
LDL-cholesterol† (mmol/l) | -0.15 (-0.6 to +0.3) | -0.3 (-0.8 to +0.2) | 0.3 (0.0 to 0.9)** | -0.15 (-0.4 to -0.2) | -0.05 (-1.5 to -0.8) |
HDL-cholesterol† (mmol/l) | 0.15 (0 to 0.20) | 0.20 (0.02 to 0.21) | 0.10 (0.00 to 0.51) | 0.20 (0.11 to 0.21) | 0.06 (-0.11 to +0.50) |
Triglycerides†(mmol/l) | -0.35 (-1.1 to -0.1) | -0.51 (-0.4 to -0.2) | -0.21 (-0.4 to +0.2) | -0.47 (-1.0 to -0.1) | -0.22 (-0.3 to +0.1) |
Time between assessments† (months) | 3 (2.5 to 3) | 3 (2.5 to 3) | 3 (2 to 3) | 3 (2.5 to 3) | 3 (2 to 3) |